Enovis Co. (NYSE:ENOV) Stock Holdings Raised by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC boosted its stake in shares of Enovis Co. (NYSE:ENOV - Free Report) by 211.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,657 shares of the company's stock after purchasing an additional 19,451 shares during the period. Tower Research Capital LLC TRC owned approximately 0.05% of Enovis worth $1,257,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in ENOV. Aster Capital Management DIFC Ltd acquired a new position in Enovis in the fourth quarter valued at $29,000. Quadrant Capital Group LLC lifted its stake in shares of Enovis by 53.0% in the 4th quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock valued at $30,000 after purchasing an additional 239 shares in the last quarter. UMB Bank n.a. grew its holdings in shares of Enovis by 128.2% during the 4th quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after purchasing an additional 437 shares during the period. Pinnacle Bancorp Inc. increased its position in Enovis by 54.5% during the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock worth $37,000 after purchasing an additional 300 shares in the last quarter. Finally, Sterling Capital Management LLC raised its holdings in Enovis by 56.2% in the fourth quarter. Sterling Capital Management LLC now owns 3,259 shares of the company's stock valued at $143,000 after buying an additional 1,173 shares during the period. 98.45% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reiterated a "buy" rating and set a $64.00 price objective on shares of Enovis in a research note on Wednesday, April 9th.

Enovis Stock Down 2.0 %

Shares of ENOV traded down $0.70 during mid-day trading on Wednesday, reaching $34.21. 102,461 shares of the stock traded hands, compared to its average volume of 752,363. The stock has a fifty day simple moving average of $36.32 and a 200 day simple moving average of $41.96. Enovis Co. has a 12-month low of $29.32 and a 12-month high of $56.43. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of -15.59 and a beta of 1.86.

Enovis (NYSE:ENOV - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, topping analysts' consensus estimates of $0.92 by $0.06. The firm had revenue of $560.98 million for the quarter, compared to analyst estimates of $555.14 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. Sell-side analysts expect that Enovis Co. will post 2.79 EPS for the current fiscal year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.